Etoposide improves survival in high-grade glioma: a meta-analysis

A Leonard, JE Wolff - Anticancer research, 2013 - ar.iiarjournals.org
Background: The purpose of this meta-analysis was to evaluate the therapeutic efficacy of
topoisomerase inhibitors in the treatment of high-grade gliomas (HGGs). Materials and …

Chemotherapy for high‐grade glioma

L Stewart, S Burdett… - Cochrane Database …, 1996 - cochranelibrary.com
Background Trials on the effect of systemic chemotherapy on survival and recurrence in
adults with high‐grade glioma have had inconclusive results. We undertook a systematic …

Phase II study of topotecan in patients with recurrent malignant glioma

D Macdonald, G Cairncross, D Stewart, P Forsyth… - Annals of oncology, 1996 - Elsevier
Summary Background The NCIC Clinical Trials Group has an ongoing interest in assessing
investigational agents in minimally pretreated patients with malignant glioma. Topotecan is …

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

DA Reardon, JA Quinn, J Vredenburgh, JN Rich… - Cancer, 2005 - Wiley Online Library
BACKGROUND In the current study, the authors report a Phase II trial of irinotecan (CPT‐
11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a …

[HTML][HTML] Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

S Nagpal, CK Recht, S Bertrand, RP Thomas… - Journal of Neuro …, 2015 - Springer
Patients with recurrence of high-grade glioma (HGG) after bevacizumab (BEV) have an
extremely poor prognosis. Etirinotecan pegol (EP) is the first long-acting topoisomerase-I …

Topoisomerase I inhibitors for the treatment of brain tumors

L Feun, N Savaraj - Expert review of anticancer therapy, 2008 - Taylor & Francis
Patients with primary malignant brain tumors have a poor prognosis. Standard treatment
includes surgical resection, radiation therapy and chemotherapy. Topoisomerase I inhibitors …

[HTML][HTML] A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models

TR Jue, ES Sena, MR Macleod, KL McDonald… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Malignant glioma is a devastating disease affecting both adults and children with limited
treatment strategies. Pre-clinical animal studies are critical to the development and planning …

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

DA Reardon, JA Quinn, JN Rich, A Desjardins… - Cancer, 2005 - Wiley Online Library
BACKGROUND The authors determined the maximum tolerated dose (MTD) and dose‐
limiting toxicity (DLT) of irinotecan (CPT‐11), a topoisomerase I inhibitor, when administered …

Chemotherapy and target therapy in the management of adult high-grade gliomas

G Paolo Spinelli, E Miele, G Lo Russo… - Current cancer drug …, 2012 - ingentaconnect.com
Adult high grade gliomas (HGG) are the most frequent and fatal primary central nervous
system (CNS) tumors. Despite recent advances in the knowledge of the pathology and the …

Temozolomide as first-line agent in treating high-grade gliomas: phase II study

S Chibbaro, L Benvenuti, A Caprio… - Journal of Neuro …, 2004 - Springer
Temozolomide a recent, oral, second generation alkylating agent is a chemotherapeutic with
demonstrated efficacy for the treatment of high-grade gliomas; its efficacy has been …